Preventing the formation of harmful proteins linked to diabetes and Alzheimer's disease
Inhibition of Human Islet Amyloid Polypeptide Aggregation
This study is looking at how a protein linked to type-2 diabetes can cause cell damage, and it hopes to find ways to stop this from happening, which could help people with diabetes and similar conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Clemson University NIH-funded |
| Lab location | 1 site (Clemson, United States) |
| Project ID | NIH-10875517 on NIH RePORTER |
What this research studies
This research investigates how the aggregation of islet amyloid polypeptide (IAPP), a protein associated with type-2 diabetes, contributes to cell death and disease progression. By utilizing advanced imaging techniques, the study aims to understand the molecular mechanisms behind IAPP aggregation and its interactions with cell membranes. The ultimate goal is to develop strategies to inhibit this aggregation, potentially preventing the harmful effects associated with diabetes and related neurodegenerative diseases. Patients may benefit from insights that could lead to new therapeutic approaches for managing these conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with type-2 diabetes or those at risk of developing diabetes and related neurodegenerative conditions.
Not a fit: Patients with type-1 diabetes or those without any amyloid-related conditions may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent or slow the progression of type-2 diabetes and its associated complications, including Alzheimer's disease.
How similar studies have performed: Other research has shown promising results in targeting amyloid aggregation in various diseases, indicating that this approach may hold potential for success.
Where this research is happening
Clemson, United States
- Clemson University — Clemson, United States (Active)
Researchers
- Principal investigator: Ding, Feng — Clemson University
- Study coordinator: Ding, Feng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.